biostudies-literatureUnknown2023Miller KM<h4>Objective</h4>To further evaluate glycemic outcomes during the observational extension phase of the Continuous Glucose Monitoring (CGM) Intervention for Teens and Young Adults randomized clinical trial (RCT). <i>Subjects and Methods</i>. Following a 26-week RCT comparing CGM with blood glucose monitoring (BGM) in 153 adolescents and young adults aged 14 to <25 years old with suboptimally controlled type 1 diabetes, 70 (89%) participants in the BGM group initiated use of CGM (referred to as BGM-CGM cohort), and 70 (95%) participants in the CGM group continued to use of CGM (CGM-CGM cohort) for an additional 26 weeks.<h4>Results</h4>In the CGM-CGM cohort, mean hemoglobin A1c (HbA1c) decreased from 8.9% ± 0.9% (74 ± 9.8 mmol/mol) at randomization to 8.3% ± 1.3% (67 ± 14.2 mmol/mol) at 52 Pediatric diabetes6718115https://www.ebi.ac.uk/biostudies/studies/S-EPMC12016685biostudies-literatureContinuous Glucose Monitoring Provides Durable Glycemic Benefit in Adolescents and Young Adults with Type 1 Diabetes: 12-Month Follow-Up Results.PMC12016685Kanapka LGWilli SMClements MAWilliams Kfor the CITY Study GroupLaffel LMLyons SKBauza CHood KPrahalad PFreiner EMoore WDeSalvo DJMesser LHCriego ASimmons JHSulik MWeinstock RSBergamo KMiller KMMonzavi RWadwa RPSherr JfalseContinuous Glucose Monitoring Provides Durable Glycemic Benefit in Adolescents and Young Adults with Type 1 Diabetes: 12-Month Follow-Up Results.<h4>Objective</h4>To further evaluate glycemic outcomes during the observational extension phase of the Continuous Glucose Monitoring (CGM) Intervention for Teens and Young Adults randomized clinical trial (RCT). <i>Subjects and Methods</i>. Following a 26-week RCT comparing CGM with blood glucose monitoring (BGM) in 153 adolescents and young adults aged 14 to <25 years old with suboptimally controlled type 1 diabetes, 70 (89%) participants in the BGM group initiated use of CGM (referred to as BGM-CGM cohort), and 70 (95%) participants in the CGM group continued to use of CGM (CGM-CGM cohort) for an additional 26 weeks.<h4>Results</h4>In the CGM-CGM cohort, mean hemoglobin A1c (HbA1c) decreased from 8.9% ± 0.9% (74 ± 9.8 mmol/mol) at randomization to 8.3% ± 1.3% (67 ± 14.2 mmol/mol) at 52 2023-01-01T00:00:00Z20232026-06-01T10:16:56.174Z2025-07-10T03:09:08.22ZS-EPMC120166854030327010.1155/2023/6718115